First identification of mcr-1/mcr-2 genes in the fecal microbiota of Canadian commercial pigs during the growing and finishing period

Mohamed Rhouma1
William Thériault1
Nassima Rabhi1
Caroline Duchaine2
Sylvain Quessy1
Philippe Fravalo1

1Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada;
2Department of Biochemistry, Microbiology and Bioinformatics, Faculty of Science and Engineering, Université Laval, Quebec, QC G1V 4G5, Canada

Colistin is considered one of the last-resort antibiotics used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) in humans.1 This antibiotic is classified by the World Health Organization, among the category of the Highest Priority Critically Important Antimicrobials for human medicine.2 In this regard, the global dissemination of plasmid-mediated colistin resistance, conferred by the mobile colistin resistance (mcr) genes, has raised serious concern among physicians and scientists worldwide.2 On the other hand, colistin has been widely used in food animals in many countries either for disease therapy, prophylaxis or for growth promotion.3 Many studies reported a high prevalence of mcr genes on bacterial isolates from animals' origin compared to humans, and consequently animals, particularly pig production, were pointed out as the greatest cause of bacterial colistin resistance spread.1 In pigs, mcr genes were isolated mainly from colistin resistant E. coli, Salmonella and Klebsiella isolates, with mcr-1 gene being the most frequently identified gene among the eight types of mcr genes currently described.1 Among other Gram-negative bacteria (GNB) of pig origin, mcr genes were identified in Moraxella spp.,4 and in Aeromonas hydrophila,5 enforcing the interest to consider the mcr presence at the microbiota level. In Canada, although colistin is not approved for use in veterinary medicine, it was sometimes used in pigs according to special precautions for the oral treatment of digestive infections caused by GNB.1 Nevertheless, mcr-1 gene has been identified in E. coli isolated from humans, as well as from lean ground beef in Canada.6 However, to the best of our knowledge, mcr genes have never been identified in animals at the farm level in Canada. Here we report the screening of fecal samples obtained from one Canadian commercial pig farm, to determine the prevalence over the growing period of mcr-1 and mcr-2 genes in the fecal microbiota of pigs. Colistin has never been used in this farm. However, tiamulin and chlortetracycline were used in the post-weaning period and salinomycin as well as narasin were used during the growing phase. The present study was primarily designed to investigate the relationship between gut microbiota composition and some welfare problems in pigs (e.g., tail biting). Fecal samples have been collected between January 2017 and April 2017, from one commercial pig farm located in the province of Quebec (Canada). Pigs were sampled 5 times during the study period. In fact, fresh fecal material was collected directly from each animal’s rectum using disposable gloves, and immediately 1 g of each sample was placed in liquid nitrogen. At the laboratory, these samples were stored at −80°C until DNA extraction. In the current study, fecal samples that have
been obtained from 62, 60, 62, 33, and 44 pigs, which correspond to the sampling time; I, II, III, IV and V respectively (Table 1), were used to identify *mcr-1* and *mcr-2* genes. Total genomic DNA was extracted using a standard Phenol-Chloroform method. All DNA extracts were screened by PCR for the presence of *mcr-1* and *mcr-2* genes, using primers and conditions as previously described. Positive samples for *mcr* (1-2) genes were confirmed by the Sanger sequencing of the amplified fragment. The *mcr-1* gene has been identified in all sampling dates. However, *mcr-2* gene was detected in three of the five sampling dates (Table 1). Only one animal harbor in its fecal microbiota both *mcr-1* gene and *mcr-2* gene, however this finding was transitory, since this result was observed only at the first sampling time. It is noteworthy that 11.4% of pigs were sent to the slaughterhouse with *mcr-1* gene in their microbiota, which could represent a threat for consumers in terms of colistin-resistance genes transfer. Our results corroborate the study of Meinersmann et al who reported the identification of *mcr-1* gene in the cecal contents of pigs in the United States, even in the absence of evidence of colistin use in pigs in this country. However, the Canadian Integrated Program for Antimicrobial Resistance Surveillance targets only the antimicrobial resistance profile of *E. coli* and *Salmonella* at pig farms, which can explain in part why the *mcr* genes have never been identified at the farm level in Canada. Our results highlight the need to expand monitoring *mcr* genes and colistin resistance to other Enterobacteriaceae species than those routinely analyzed. In our study, the bacterial genus harboring the *mcr-1* and/or the *mcr-2* genes was not identified. However, we unequivocally confirm the presence of these genes in the microbiota of pigs in a conventional facility. It should be stressed here that *mcr-1* and *mcr-2* genes have been identified in the fecal microbiota of pigs that have never been treated with colistin. Such presence could be related to the possible contamination of feed by bacteria harboring these genes. In fact, *mcr-1* gene has already been isolated from colistin-resistant *E. coli* recovered form animal feed. On the other hand, *mcr-1* gene was identified in 60% of air samples from finishing swine barns in Canada. Thereby, swine confinement buildings could be also a source of contamination for pigs. Moreover, based on known co-localization of *mcr* genes with other antimicrobial genes within the same mobile genetic elements, selective pressure imposed by other antimicrobials could favor the selection of *mcr* genes, even in the absence of colistin use. Indeed, it was reported that a colistin-resistant *E. coli* strain derived from animal origin harbored on the same plasmid, in addition to *mcr-1* gene, several resistance-encoding genes such as; trimethoprim (*dfrA1*), tetracycline (*tetA*),

**Table 1** Detection of *mcr-1* and *mcr-2* genes in the fecal microbiota in a Canadian commercial pigs farm during the growing and finishing period, 2017

<table>
<thead>
<tr>
<th>Sampling number</th>
<th>Fecal samples number</th>
<th>Number of <em>mcr-1</em> positives samples/(in %)</th>
<th>Number of <em>mcr-2</em> positives samples/(in %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>34 days</td>
<td>6 (9.7)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>II</td>
<td>47 days</td>
<td>15 (25.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>III</td>
<td>67 days</td>
<td>1 (1.6)</td>
<td>6 (9.7)</td>
</tr>
<tr>
<td>IV</td>
<td>75 days</td>
<td>3 (9.1)</td>
<td>4 (6.5)</td>
</tr>
<tr>
<td>V</td>
<td>109 days</td>
<td>5 (11.4)</td>
<td>12 (28.6)</td>
</tr>
</tbody>
</table>

Notes: Fecal samples derived from the same animals (N=3), were positive for *mcr-1* gene at I and III. Fecal samples derived from the same animals (N=2), were positive for *mcr-2* gene at I and IV.
aminoglycoside (aadA1, aph(6)-Id or strA, and aph(3′)-Ib/strB), and sulphonamide (sul1) antibiotics. In our study, the use of chlorotetracycline could be associated with a selective pressure on mcr genes. However, to the best of our knowledge, neither cross-resistance between colistin and coccidiostat ionophore drugs (e.g., salinomycin, narasin), nor between colistin and tiamulin has been reported in the scientific literature.

Further studies are needed to determine the role of the selection pressure by other antimicrobials as well as pig’s environment and feed in the dissemination of colistin resistance genes in pigs.

Acknowledgments
This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) (520873-17).

Disclosure
The authors report no conflicts of interest in this work.

References

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Veterinary Medicine: Research and Reports ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Veterinary Medicine: Research and Reports editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.